Fortune Medicines Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 16 Year, 1 Month
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 1.20 M
- Revenue Growth 351.63%
- Profit Growth 89.02%
- Ebitda 91.75%
- Net Worth -2.41%
- Total Assets 29.15%
About Fortune Medicines
Fortune Medicines Private Limited (FMPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 December 2008 and has a history of 16 years and one month. Its registered office is in New Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.20 M.
Komal Chauhan, Anita Chauhan, and Praveen Chauhan serve as directors at the Company.
Company Details
-
Location
New Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232DL2008PTC185878
-
Company No.
185878
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
16 Dec 2008
-
Date of AGM
31 Dec 2020
-
Date of Balance Sheet
31 Mar 2020
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Fortune Medicines?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Komal Chauhan
|
Director | 30-Sep-2019 | Current |
|
Anita Chauhan
|
Director | 30-Sep-2019 | Current |
|
Praveen Chauhan
|
Director | 30-Dec-2015 | Current |
Financial Performance of Fortune Medicines.
Fortune Medicines Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 351.63% increase. The company also saw a substantial improvement in profitability, with a 89.02% increase in profit. The company's net worth dipped by a decrease of 2.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fortune Medicines?
In 2017, Fortune Medicines had a promoter holding of 50.00% and a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.20 M
₹0
Charges Breakdown by Lending Institutions
- Syndicate Bank : 0.12 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Jan 2015 | Syndicate Bank | ₹1.20 M | Open |
How Many Employees Work at Fortune Medicines?
Unlock and access historical data on people associated with Fortune Medicines, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fortune Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fortune Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
